CORT Q2 2023 Earnings — Corcept Therapeutics Incorporated Revenue & Financial Results | Market Cap Arena

CORTCorcept Therapeutics Incorporated

$4B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$118M+13.9% YoY

Gross Profit

$116M98.7% margin

Operating Income

$30M25.1% margin

Net Income

$28M23.4% margin

EPS (Diluted)

$0.25

QoQ Revenue Growth

+11.4%

Cash Flow

Operating Cash Flow

$42M

Free Cash Flow

$42M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$525M

Total Liabilities

$103M

Stockholders' Equity

$422M

Cash & Equivalents

$172M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$118M	$103M	+13.9%
Gross Profit	$116M	$102M	+13.8%
Operating Income	$30M	$31M	-5.9%
Net Income	$28M	$27M	+0.4%